Biosig Technologies (NASDAQ:STEX) Shares Gap Up Following Insider Buying Activity

Shares of Biosig Technologies, Inc. (NASDAQ:STEX) gapped up prior to trading on Wednesday after an insider bought additional shares in the company. The stock had previously closed at $3.65, but opened at $3.88. Biosig Technologies shares last traded at $3.76, with a volume of 1,599,808 shares.

Specifically, major shareholder Frank Giustra acquired 1,000,000 shares of the business’s stock in a transaction dated Friday, January 23rd. The stock was bought at an average price of $3.00 per share, with a total value of $3,000,000.00. Following the purchase, the insider owned 1,178,205 shares of the company’s stock, valued at approximately $3,534,615. This trade represents a 561.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Morgan Lee Lekstrom purchased 23,000 shares of the business’s stock in a transaction on Monday, January 26th. The shares were acquired at an average price of $3.30 per share, with a total value of $75,900.00. Following the completion of the transaction, the director owned 71,000 shares of the company’s stock, valued at approximately $234,300. This trade represents a 47.92% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In related news, Director Morgan Lee Lekstrom acquired 41,000 shares of the firm’s stock in a transaction dated Friday, January 23rd. The shares were purchased at an average price of $3.13 per share, for a total transaction of $128,330.00. Following the completion of the acquisition, the director owned 48,000 shares in the company, valued at approximately $150,240. This represents a 585.71% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings initiated coverage on Biosig Technologies in a report on Friday, January 23rd. They set a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Key Headlines Impacting Biosig Technologies

Here are the key news stories impacting Biosig Technologies this week:

• Positive Sentiment: Major shareholder Frank Giustra purchased 1,000,000 shares at about $3.00 (~$3.0M), a large vote of confidence that likely supported buying interest. SEC Filing
• Positive Sentiment: CIO Mitchell Young Williams acquired 51,511 shares, further reinforcing insider accumulation and signaling management conviction in the company’s outlook. Article
• Positive Sentiment: Director Morgan Lee Lekstrom executed multiple buys (including 41,000; 23,000; and 5,500‑share transactions at ~\$3.13–\$3.30), materially increasing her stake — another supportive insider pattern. InsiderTrades
• Neutral Sentiment: Press releases tied to the STEX ticker report closings of public offerings and full exercise of over‑allotment (total gross proceeds announced up to ~$40.25M). That increases liquidity but implies share issuance/dilution; the net effect depends on whether these filings refer to the same legal issuer and how proceeds are deployed. GlobeNewswire
• Negative Sentiment: Weiss Ratings initiated coverage with a “sell (d-)” rating and MarketBeat shows an average analyst view of “Sell” — negative third‑party sentiment that can limit upside despite insider buying. Weiss Ratings

Biosig Technologies Stock Performance

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.